Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tak-901. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB known ✓ | Q96GD4 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | STK3 | Q13188 | 2/20 | 1.00 |
| ▸ | MELK | Q14680 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tak-901 SCHEMBL29478939 | 1.00 | FLT3 (1.00) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL29551559 | 1.00 | FLT3 (1.00) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL29389353 | 1.00 | FLT3 (1.00) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2123148 | 0.99 | FLT3 (0.98) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL646980 | 0.99 | FLT3 (0.98) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2125658 | 0.98 | FLT3 (0.97) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2122890 | 0.98 | FLT3 (0.97) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2125119 | 0.98 | FLT3 (0.96) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2121299 | 0.96 | FLT3 (0.93) | FLT3RPS6KA3PRKAA1STK3MELK | |
| Tak-901 SCHEMBL2121923 | 0.96 | FLT3 (0.93) | FLT3RPS6KA3PRKAA1STK3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117821369-A | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | 詹森生物科技公司 | 2024-04-05 | — | — | CN | claimed |
| EP-3954759-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | Janssen Biotech, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3143127-B1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | JANSSEN BIOTECH INC (US) | 2021-07-14 | — | — | EP | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2145877-B1 | Aurora Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-10-03 | — | — | EP | claimed |
| US-8119655-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-21 | — | — | US | claimed |
| JP-2011513201-A | — | — | 2011-04-28 | — | — | JP | claimed |
| US-20100331357-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | claimed |
| EP-2252291-A1 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20100190816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2145877-A2 | Aurora Kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2010-01-20 | — | — | EP | claimed |
| WO-2009107877-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-03 | — | — | WO | claimed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | claimed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331357-A1 | PHARMACEUTICAL COMPOSITION | ABCG2, GYS2, CEL | AURKB 2551/4885FLT3 1540/4885RPS6KA3 3839/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKB 130/4885FLT3 209/4885RPS6KA3 72/4885 |
| US-20100190816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | AURKB 130/4885FLT3 209/4885RPS6KA3 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.